Perelel reports significant metabolic and cognitive findings from four-week protein supplement trial

Perelel Inc. has reported new results from a randomized, double-blind, placebo-controlled study of Triple-Support Protein, saying four weeks of daily supplementation produced statistically significant improvements in total cholesterol and LDL cholesterol within normal ranges, increased feelings of fullness and improved spatial-memory performance among women aged 30 to 60. The study involved 39 participants with an average age of 46 and tested Perelel’s combination of plant-based protein, creatine monohydrate and low-FODMAP prebiotic fiber against placebo, moving the privately held women’s health company beyond relying solely on research conducted on the formula’s individual ingredients. The findings potentially strengthen Perelel’s effort to distinguish a premium consumer supplement through product-specific clinical evidence, particularly after the company secured a $27 million growth investment from Prelude Growth Partners and existing investors in late 2025. However, the company’s headline assertion that the study “proves efficacy” goes further than the currently available evidence allows, because complete effect sizes, p-values, safety results and a peer-reviewed analysis have not yet been made public, while the corresponding ClinicalTrials.gov record still lists the study as recruiting with no results posted.

The distinction is important because the trial design itself appears considerably stronger than the typical testimonial or ingredient-based evidence used to market many nutritional products. The registered GLOW Study is sponsored by the University of North Carolina at Chapel Hill with Perelel as a collaborator and principal investigator Abbie Smith-Ryan, a professor and director of UNC’s Applied Physiology Laboratory. It was designed as a randomized, double-blind, placebo-controlled parallel study in healthy women, with an estimated enrollment of 40 and planned assessment of metabolic, body-composition and well-being outcomes. That structure makes the newly reported findings worth examining, but rigorous trial design and conclusive proof are not the same thing, particularly when the full statistical dataset remains unavailable for independent assessment.

What did Perelel actually report from the Triple-Support Protein clinical study?

Perelel said women receiving Triple-Support Protein showed statistically significant improvements relative to placebo in total cholesterol and LDL cholesterol after four weeks, with both measures already within normal ranges. Participants also reported greater feelings of fullness and demonstrated improved spatial-memory performance, according to the company. Perelel described these findings as supporting the formula’s potential role across metabolic and cognitive health, while emphasizing that this is direct evidence on the combined product rather than extrapolation from studies of pea protein, creatine or fiber conducted separately.

Several details are encouraging from a research perspective. The trial used a placebo comparator, both participants and investigators were blinded, and the population consisted of women aged 30 to 60 rather than extrapolating findings from studies dominated by younger men. That matters because Perelel is increasingly targeting women beyond pregnancy and postpartum nutrition, including customers moving through midlife and perimenopause, where preservation of muscle mass, metabolic health and cognitive performance are commercially important concerns.

What has not been disclosed is equally important. Perelel’s announcement does not give the absolute reduction in LDL or total cholesterol, the percentage change from baseline, confidence intervals or individual p-values. It also does not quantify the improvement in spatial memory or fullness, making it impossible to determine from the announcement alone whether the statistically significant differences were large enough to be clinically or practically meaningful.

Statistical significance answers whether an observed difference is unlikely to be explained by random variation under the study model. It does not automatically establish that the size of the change is meaningful enough to alter health outcomes or consumer experience.

Why does the registered primary endpoint make Perelel’s glucose-regulation language worth examining carefully?

The ClinicalTrials.gov registration makes the interpretation more complicated because the prespecified primary outcome was change in postprandial glucose area under the curve following a standardized meal. Secondary registered outcomes include insulin sensitivity measured through HOMA-IR and change in lean soft tissue measured using DXA. The study was designed to examine how the intervention affected blood glucose over the two hours following a standardized meal, making glycemic control a central component of the original research question.

Perelel’s August announcement says the findings support Triple-Support Protein’s role in glucose regulation, but the company does not explicitly state that the primary glucose AUC endpoint achieved statistical significance. Instead, the release specifically identifies total cholesterol, LDL cholesterol, fullness and spatial-memory performance as outcomes with statistically significant improvements compared with placebo.

That difference should not be ignored.

It is possible that glucose-related results were favorable without reaching statistical significance, that additional analyses produced supportive findings, or that fuller results will clarify the outcome when published. The current public information does not allow those possibilities to be resolved. Until the complete dataset becomes available, it would be premature to present Triple-Support Protein as having demonstrated a statistically significant improvement in glycemic control simply because glucose regulation appears in Perelel’s broader interpretation of the findings.

The eventual publication should therefore answer a straightforward question: what happened to the trial’s prespecified primary endpoint?

That answer will be more informative than the number of positive secondary or exploratory measures highlighted in a commercial announcement.

Why does the ClinicalTrials.gov record still showing “recruiting” create an unusual disclosure gap?

As of August 20, the public ClinicalTrials.gov entry for NCT07526571 still identifies the GLOW Study as recruiting, with estimated primary and final completion dates of December 1, 2026. The registry continues to show estimated enrollment of 40 participants and states that no study results have been posted. Its last listed update was submitted in April and posted on April 13.

Perelel, by contrast, says a four-week study has already been conducted in 39 women and is announcing outcomes from it.

That does not necessarily mean the underlying research is inconsistent. ClinicalTrials.gov records can lag behind actual recruitment and study activity when responsible parties have not yet submitted updated status information, and Perelel’s reported enrollment of 39 is close to the registered target of 40. The discrepancy nevertheless matters editorially because the independently accessible registry has not yet been updated to corroborate study completion or provide structured results.

A completed and updated registry record would clarify final enrollment, participant disposition, outcome measurements and any protocol changes. Publication of a full manuscript or scientific abstract would provide the statistical information needed to evaluate the claims more thoroughly.

Perelel has stated that de-identified individual participant data may eventually be shared with qualified researchers following primary results publication, subject to institutional and regulatory requirements. If that occurs, the trial could ultimately provide considerably more transparency than is currently available from the company announcement alone.

What is actually inside Perelel Triple-Support Protein and how does its formulation support the study rationale?

Each serving of the commercially available Triple-Support Protein contains 20 grams of pea protein, 5 grams of dietary fiber and 3 grams of creatine monohydrate, alongside 120 calories and no added sugar. Perelel uses cassava-root fiber as the prebiotic component and markets the formulation as a combination intended to support muscle, digestive and cognitive health. A 15-serving package currently costs $47 as a one-time purchase, equivalent to approximately $3.13 per serving, while the company lists a subscription price of $39.95, or around $2.66 per serving.

The combination is commercially logical because all three components address areas attracting growing interest among women in midlife.

Protein supports maintenance and development of lean tissue, while creatine has one of the deeper research histories among sports-nutrition ingredients and has increasingly attracted attention for potential cognitive as well as muscular applications. Fiber contributes to digestive function and can influence satiety and aspects of metabolic health.

Perelel’s commercial proposition is that combining the three simplifies supplementation and may produce useful complementary effects. The new study is important precisely because research on three ingredients independently cannot establish that one commercial combination will necessarily reproduce all of those benefits in the intended user population.

Testing the finished formula therefore represents a higher evidentiary standard than citing a collection of ingredient studies. The question now is whether the magnitude and reproducibility of the observed effects are strong enough to support the product’s premium positioning.

Why could direct clinical trials become a commercial differentiator in the women’s supplement market?

Perelel has increasingly made clinical research part of its brand strategy rather than treating it exclusively as a product-development exercise. The company said it completed multiple placebo-controlled trials across products during 2025 and 2026, including studies involving its Conception Support Pack, Synbiotic Greens Powder and Perimenopause Support Pack. Triple-Support Protein extends that approach into a category where consumers already have a large selection of protein, creatine and fiber products available separately.

That creates an important commercial challenge for Perelel. Consumers can purchase basic pea protein, creatine monohydrate and fiber without paying for a branded three-in-one women’s formulation. Perelel therefore needs to justify not simply the ingredients but the convenience, quality controls, formulation and evidence around the complete product.

Product-specific clinical research can help create that differentiation if the results are strong enough.

The company’s $27 million growth investment announced in November 2025 gives it additional resources to pursue that strategy. Prelude Growth Partners led the investment with participation from Unilever Ventures, Willow Growth Partners and Selva Ventures, and Perelel said at the time that the funding would support its evolution from a prenatal-focused business into a broader women’s health company. Perelel also described itself as profitable and growing, although it did not publish revenue, EBITDA or other financial figures that would allow those statements to be independently quantified.

Triple-Support Protein fits directly into that expansion because it is relevant far beyond pregnancy. Perelel currently markets it across stages ranging from preconception and pregnancy through postpartum, motherhood and perimenopause, potentially giving the product a much longer customer lifecycle than a trimester-specific prenatal supplement.

Does a statistically significant fall in normal LDL cholesterol establish a meaningful metabolic-health benefit?

This is where interpretation requires restraint.

Perelel specifically notes that participants’ cholesterol and LDL cholesterol were already within normal ranges. A statistically significant improvement inside a normal range may still represent a favorable biomarker change, but its clinical importance depends heavily on the starting values, absolute change, participant characteristics and durability of the effect. None of those details is quantified in the current announcement.

A four-week study is also designed primarily to detect relatively short-term physiological changes rather than demonstrate prevention of long-term cardiovascular or metabolic disease. The product is a dietary supplement, not an approved cholesterol-lowering medicine, and Perelel itself includes the standard statement that its claims have not been evaluated by the U.S. Food and Drug Administration and that the product is not intended to diagnose, treat, cure or prevent disease.

That regulatory context matters because dietary supplement structure-and-function claims are handled differently from drug efficacy claims. The FDA states that companies making such claims must possess substantiation that the statements are truthful and not misleading, but the claims are not pre-approved by the agency. Products using them must also carry the required disclaimer explaining that FDA has not evaluated the claim and that the supplement is not intended to diagnose, treat, cure or prevent disease.

Perelel’s new trial can therefore strengthen the substantiation behind product positioning without turning Triple-Support Protein into a pharmaceutical treatment.

Why is the spatial-memory result commercially interesting even though the evidence remains preliminary?

The spatial-memory finding potentially gives Triple-Support Protein a point of differentiation beyond conventional protein powders, particularly because creatine is increasingly discussed in relation to brain energy and cognition rather than muscle performance alone. Perelel says women taking the product demonstrated significantly improved spatial-memory performance relative to placebo after four weeks.

For a brand targeting women in their 30s, 40s and 50s, cognitive positioning could broaden the reason customers use the product. A protein supplement bought purely for muscle support competes in an extremely crowded category. A formulation positioned around muscle, satiety, digestive health and cognition potentially occupies a more distinctive part of the market.

The evidence threshold should rise accordingly.

The current trial registration publicly lists glucose AUC as the primary outcome and HOMA-IR and lean soft tissue as secondary outcomes. Spatial memory is not among the outcomes visible in the summarized ClinicalTrials.gov record, although the study description refers more broadly to cognition and overall well-being. That means the eventual complete protocol or publication will be important for establishing exactly how the cognitive endpoint was specified and analyzed.

This does not invalidate the result, but it affects how strongly it should be generalized. A positive exploratory cognitive finding in a 39-person study can be a reason for larger research rather than definitive evidence that the product broadly improves cognition in women.

Can Perelel turn clinical validation into a defensible advantage after its $27 million growth investment?

The business case becomes stronger if product-specific studies influence customer acquisition, retention and pricing power rather than functioning mainly as marketing content.

Perelel has built its brand around stage-specific women’s nutrition, initially focusing heavily on fertility, pregnancy and postpartum products before extending into menstrual, metabolic and perimenopause support. Triple-Support Protein is particularly relevant to that expansion because one product can theoretically remain in a customer’s routine across multiple life stages, improving lifetime value if adoption persists.

At $47 for 15 servings on a one-time basis, daily use would require roughly two bags per month and therefore approximately $94 of monthly spending before discounts. A subscriber using one serving every day would require similar product volume even at the lower per-serving subscription price. That makes repeat purchase and perceived benefit commercially critical because consumers can assemble protein, creatine and fiber separately at different price points.

Clinical evidence can help support premium pricing, but only if consumers and healthcare professionals view the research as credible. Perelel’s decision to use a randomized, double-blind, placebo-controlled design and collaborate with a university laboratory is therefore strategically sensible.

The company can strengthen that advantage considerably by publishing the complete results rather than relying on selective topline disclosure. Effect sizes, confidence intervals, all prespecified endpoints, adverse events and participant disposition would allow healthcare professionals and scientifically minded consumers to judge the evidence on its merits.

What evidence would make Perelel’s Triple-Support Protein study substantially more convincing?

The next meaningful milestone is not another marketing claim but the full dataset.

Publication should show whether the prespecified postprandial glucose AUC endpoint changed significantly, how insulin sensitivity and body composition performed, and how large the reported cholesterol, satiety and spatial-memory effects actually were. Safety and tolerability data are also relevant because a daily supplement intended for repeated use needs evidence not only that selected outcomes improved but that participants tolerated the formula over the intervention period.

A registry update would resolve the current mismatch between Perelel’s completed 39-participant study announcement and the ClinicalTrials.gov record that still describes the trial as recruiting with completion expected in December. Peer review would add another level of scrutiny by exposing the methods, statistical analysis and interpretation to researchers outside Perelel’s commercial communications process.

Replication would then become the stronger test.

Thirty-nine women can provide useful early evidence, especially under a controlled randomized design, but a larger and longer study would give greater confidence that the observed effects are reproducible across different ages, baseline diets, hormonal stages and metabolic profiles. Longer follow-up would also help establish whether changes observed after four weeks persist with continued use.

Perelel deserves credit for testing the finished Triple-Support Protein formula in the population it is attempting to serve rather than simply attaching unrelated ingredient studies to the product. The reported cholesterol, fullness and spatial-memory findings give the company a potentially valuable evidence base as it uses new growth capital to expand beyond prenatal nutrition. What the current announcement does not yet justify is the much stronger conclusion that efficacy has been conclusively proven across metabolic and cognitive health. The decisive evidence will come when Perelel and the UNC research team disclose the complete prespecified results and allow the magnitude, consistency and clinical relevance of those findings to be evaluated rather than inferred from statistical significance alone.

What are the key takeaways from Perelel’s Triple-Support Protein clinical study?

• Perelel reported results from a randomized, double-blind, placebo-controlled four-week study involving 39 women aged 30 to 60, with an average age of 46.
• The company said Triple-Support Protein produced statistically significant improvements versus placebo in total cholesterol and LDL cholesterol within normal ranges, feelings of fullness and spatial-memory performance.
• Perelel did not disclose effect sizes, confidence intervals or individual p-values for the positive findings in its August 20 announcement.
• The registered GLOW Study identified postprandial glucose AUC as its primary outcome, but Perelel did not explicitly state that this primary endpoint achieved statistical significance.
• ClinicalTrials.gov still lists NCT07526571 as recruiting with no results posted and an estimated December 2026 completion date, despite Perelel announcing completed four-week results.
• Triple-Support Protein provides 20 grams of pea protein, 5 grams of fiber and 3 grams of creatine monohydrate per serving.
• The product currently costs $47 for 15 servings as a one-time purchase, with a lower subscription price, positioning clinical evidence as potentially important to its premium consumer proposition.
• Perelel secured a $27 million growth investment led by Prelude Growth Partners in November 2025 as it expands beyond prenatal nutrition into broader women’s health categories.
• Dietary supplement structure-and-function claims are not pre-approved by the FDA, and Perelel states that Triple-Support Protein is not intended to diagnose, treat, cure or prevent disease.
• The strongest next proof points are publication of the complete trial results, an updated study registry and larger or longer-term replication of the reported metabolic and cognitive findings.